Related references
Note: Only part of the references are listed.Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline From the American College of Physicians
Amir Qaseem et al.
ANNALS OF INTERNAL MEDICINE (2012)
Comparative Effectiveness of Sulfonylurea and Metformin Monotherapy on Cardiovascular Events in Type 2 Diabetes Mellitus A Cohort Study
Christianne L. Roumie et al.
ANNALS OF INTERNAL MEDICINE (2012)
Mortality After Incident Cancer in People With and Without Type 2 Diabetes Impact of metformin on survival
Craig J. Currie et al.
DIABETES CARE (2012)
Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials
R. J. Stevens et al.
DIABETOLOGIA (2012)
Rosiglitazone and the Risk of Adverse Cardiovascular Outcomes
A. G. Winterstein
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Is There Clear and Convincing Evidence of Cardiovascular Risk with Rosiglitazone?
S. Kaul et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study
Tina Ken Schramm et al.
EUROPEAN HEART JOURNAL (2011)
Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies
Yoon Kong Loke et al.
BRITISH MEDICAL JOURNAL (2011)
Rosiglitazone Revisited An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality
Steven E. Nissen et al.
ARCHIVES OF INTERNAL MEDICINE (2010)
Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone
David J. Graham et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Smoking Prevalence among US Veterans
David W. Brown
JOURNAL OF GENERAL INTERNAL MEDICINE (2010)
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Philip D. Home et al.
LANCET (2009)
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database
Ioanna Tzoulaki et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study
David N. Juurlink et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Propensity scores
Peter Cummings
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE (2008)
Thiazolidinediones and cardiovascular outcomes in older patients with diabetes
Lorraine L. Lipscombe et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Long-term risk of cardiovascular events with rosiglitazone - A meta-analysis
Sonal Singh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration
Kristijan H. Kahler et al.
DIABETES CARE (2007)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A systematic review and meta-analysis of hypoglycemia and cardiovascular event - A comparison of glyburide with other secretagogues and with insulin
Azim S. Gangji et al.
DIABETES CARE (2007)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods
T Stürmer et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2006)
Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin
JMM Evans et al.
DIABETOLOGIA (2006)
Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study
SH Simpson et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2006)
Improved clinical outcomes associated with metformin in patients with diabetes and heart failure
DT Eurich et al.
DIABETES CARE (2005)
Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review
BR Shah et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2005)
Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study
M Gulliford et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2004)
Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes
AJ Garber et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea
BJ Goldstein et al.
CLINICAL THERAPEUTICS (2003)
Evaluating medication effects outside of clinical trials: New-user designs
WA Ray
AMERICAN JOURNAL OF EPIDEMIOLOGY (2003)
Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes
JA Johnson et al.
DIABETES CARE (2002)
A primer and comparative review of major US mortality databases
DC Cowper et al.
ANNALS OF EPIDEMIOLOGY (2002)
Share Paper
